UBS Group Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics (NASDAQ:UTHR) had its target price hoisted by UBS Group from $415.00 to $475.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other analysts have also commented on the stock. LADENBURG THALM/SH SH boosted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. The Goldman Sachs Group raised their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, December 30th. TD Cowen raised their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $378.36.

United Therapeutics Price Performance

NASDAQ UTHR opened at $366.61 on Wednesday. The stock’s 50-day moving average is $370.83 and its 200-day moving average is $351.77. United Therapeutics has a one year low of $208.62 and a one year high of $417.82. The firm has a market cap of $16.37 billion, a P/E ratio of 16.10, a P/E/G ratio of 1.05 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter last year, the firm earned $5.38 EPS. Equities analysts anticipate that United Therapeutics will post 25.22 EPS for the current year.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 7,792 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $355.88, for a total value of $2,773,016.96. Following the completion of the transaction, the chief financial officer now directly owns 5,884 shares in the company, valued at approximately $2,093,997.92. The trade was a 56.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $356.68, for a total transaction of $3,566,800.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $919,164.36. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 142,422 shares of company stock worth $53,498,732. Corporate insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently modified their holdings of UTHR. Renaissance Technologies LLC lifted its position in shares of United Therapeutics by 1.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after buying an additional 22,978 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of United Therapeutics by 4.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock valued at $391,459,000 after purchasing an additional 45,566 shares in the last quarter. FMR LLC increased its holdings in United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares in the last quarter. Dimensional Fund Advisors LP raised its position in United Therapeutics by 4.0% in the second quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after purchasing an additional 22,683 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its stake in shares of United Therapeutics by 0.9% during the third quarter. Pacer Advisors Inc. now owns 566,703 shares of the biotechnology company’s stock valued at $203,078,000 after purchasing an additional 4,869 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.